These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3041014)

  • 21. Comparative restriction endonuclease analysis of varicella-zoster virus clinical isolates.
    Takayama M; Takayama N; Kameoka Y; Hachimori K; Kaneda K; Minamitani M
    Med Microbiol Immunol; 1989; 178(2):61-7. PubMed ID: 2543893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Varicella-zoster virus (VZV)].
    Kanai K; Yamada S; Inoue N
    Uirusu; 2010 Dec; 60(2):197-207. PubMed ID: 21488333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular and therapeutic aspects of varicella-zoster virus infection.
    Quinlivan M; Breuer J
    Expert Rev Mol Med; 2005 Aug; 7(15):1-24. PubMed ID: 16098235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in antibody responses in varicella, herpes zoster and after vaccination.
    Kimoto T; Kurimura T
    Arch Virol; 1979; 59(1-2):59-67. PubMed ID: 218537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Class-specific antibody responses to early and late antigens of varicella and herpes simplex viruses.
    Schmidt NJ; Gallo D
    J Med Virol; 1984; 13(1):1-12. PubMed ID: 6319583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and characterization of a live varicella vaccine (Oka strain).
    Takahashi M
    Biken J; 1984 Sep; 27(2-3):31-6. PubMed ID: 6100054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppressor of Cytokine Signaling 3 Expression Induced by Varicella-Zoster Virus Infection Results in the Modulation of Virus Replication.
    Choi EJ; Lee CH; Shin OS
    Scand J Immunol; 2015 Oct; 82(4):337-44. PubMed ID: 26072679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental infection of Cynomolgus Macaques (Macaca fascicularis) with human varicella-zoster virus.
    Willer DO; Ambagala AP; Pilon R; Chan JK; Fournier J; Brooks J; Sandstrom P; Macdonald KS
    J Virol; 2012 Apr; 86(7):3626-34. PubMed ID: 22258257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular dissection of the humoral immune response to individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection, and reactivation.
    Weigle KA; Grose C
    J Infect Dis; 1984 May; 149(5):741-9. PubMed ID: 6327848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human Embryonic Stem Cell-Derived Neurons Are Highly Permissive for Varicella-Zoster Virus Lytic Infection.
    Sadaoka T; Schwartz CL; Rajbhandari L; Venkatesan A; Cohen JI
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29046461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content.
    Bergen RE; Diaz PS; Arvin AM
    J Infect Dis; 1990 Nov; 162(5):1049-54. PubMed ID: 2172393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VZV infection of keratinocytes: production of cell-free infectious virions in vivo.
    Gershon MD; Gershon AA
    Curr Top Microbiol Immunol; 2010; 342():173-88. PubMed ID: 20225011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of a varicella-zoster virus glycoprotein E epitope.
    Vafai A; Forghani B; Kilpatrick D; Ling J; Shankar V
    Arch Virol; 2000; 145(1):85-97. PubMed ID: 10664408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiation of wild-type varicella-zoster strains from India and the Oka vaccine strain using a VZV open reading frame - 62 based PCR-RFLP technique.
    Kaushik KS; Lahiri KK; Kapila K; Kumar S; Gupta RM; Karade S
    Braz J Infect Dis; 2008 Aug; 12(4):313-5. PubMed ID: 19030732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection.
    Hammond O; Wang Y; Green T; Antonello J; Kuhn R; Motley C; Stump P; Rich B; Chirmule N; Marchese RD
    J Med Virol; 2006 Dec; 78(12):1679-87. PubMed ID: 17063506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zoster vaccine: current status and future prospects.
    Oxman MN
    Clin Infect Dis; 2010 Jul; 51(2):197-213. PubMed ID: 20550454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VZV T cell-mediated immunity.
    Weinberg A; Levin MJ
    Curr Top Microbiol Immunol; 2010; 342():341-57. PubMed ID: 20473790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-capture enzyme-linked immunosorbent assays that use enzyme-labelled antigen for detection of virus-specific immunoglobulin M, A and G in patients with varicella or herpes zoster.
    van Loon AM; van der Logt JT; Heessen FW; Heeren MC; Zoll J
    Epidemiol Infect; 1992 Feb; 108(1):165-74. PubMed ID: 1312479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain.
    Sauerbrei A; Eichhorn U; Gawellek S; Egerer R; Schacke M; Wutzler P
    J Med Virol; 2003 Oct; 71(2):313-9. PubMed ID: 12938208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies to the three major glycoproteins of varicella-zoster virus: search for the relevant host immune response.
    Brunell PA; Novelli VM; Keller PM; Ellis RW
    J Infect Dis; 1987 Sep; 156(3):430-5. PubMed ID: 3039010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.